Please login to the form below

Not currently logged in
Email:
Password:

Emperra appoints Bent Johnsen as CEO

He also takes on an MD role at the German digital health start-up

Bent JohnsenDigital health and medical device start-up Emperra has appointed Bent Johnsen as its CEO and managing director at time when the group bolsters Esysta, a diabetes management system that is expected to be available internationally.

Johnsen’s expertise lies in the health care sector and he has held several executive leadership positions within the field of diabetes working for insulin manufacturing companies as well as other global medical device firms.

As part of that he had a 15-year spell with Novo Nordisk, where his roles included general manager for its affiliates in Finland and the Baltic region, general manager for Poland and VP of US marketing.

He said: “I am very excited about the Esysta solution and its benefits for patients, doctors and nurses.

“The data is supported using algorithms and is the most comprehensive system available on the market.

“I’m looking forward to expanding this concept within our organisation or via strategic partners.”

Johnsen succeeds Dr Christian Krey who will be leaving the company by the end of June 2017.

Dr Klaus Stöckemann, chairman of the board at Emperra, said: “It is a great pleasure to welcome Mr. Johnsen as the new CEO of Emperra.”

“His solid international management experience is seen as very valuable at this stage where Emperra is progressing rapidly to make the innovative Esysta available both in Germany and internationally.”

6th June 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics